PT-112
Sponsors
Promontory Therapeutics Inc., SciClone Pharmaceuticals International (Cayman) Development Limited, National Cancer Institute (NCI), SciClone Pharmaceuticals
Conditions
Advanced Solid TumorBiliary Tract CancerMultiple MyelomaNon-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)Recurrent ThymomaThymic CancerThymic Epithelial Tumor
Phase 1
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
NCT02884479
Start: 2016-08-31End: 2019-03-31Target: 75Updated: 2018-04-25
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
CompletedNCT03288480
Start: 2017-12-15End: 2021-03-01Updated: 2022-04-26
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
CompletedNCT03409458
Start: 2018-04-24End: 2022-08-31Updated: 2023-11-18
PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors
NCT05357196
Start: 2020-04-13End: 2023-04-28Target: 68Updated: 2022-05-02
A Phase 1, Open-Label, Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Patients with Advanced Solid Tumors and Subsequent Expansion Cohorts
Active, not recruitingCTIS2024-518506-41-00
Start: 2020-10-05Target: 40Updated: 2025-10-09